• Je něco špatně v tomto záznamu ?

Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs

M. Hruby, K. Agrawal, O. Policianova, J. Brus, J. Skopal, P. Svec, M. Otmar, P. Dzubak, P. Stepanek, M. Hajduch

. 2016 ; 160 (2) : 222-230. [pub] 20160321

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17012972

BACKGROUND: The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs is confounded by their hydrolytic lability which decreases plasma circulation time. Here, we describe a new biodegradable, polyanhydride formulation for drug delivery that circumvents this drawback. METHODS: Injectable/implantable polymeric microbeads containing dispersed microcrystals of hydrophilic AZA or DAC packed in a dry environment are protected from hydrolysis, until the hydrolytic zone reaches the core. Diclofenac is embedded into the formulation to decrease any local inflammation. The efficacy of the formulations was confirmed by monitoring the induced demethylation, and cytostatic/cytotoxic effects of continuous drug release from the time-course dissolution of the microbeads, using an in vitro developed cell based reporter system. RESULTS: Poly(sebaccic acid-co-1,4-cyclohexanedicarboxylic acid) containing 30 wt. % drug showed zero-order release (R(2) = 0.984 for linear regression), and release rate of 10.0 %/h within the first 5 h, and subsequent slower release of the remaining drug, thus maintaining the level of drugs in the outer environment considerably longer than the typical plasma half-life of free azanucleosides. At lower concentrations, the differences between powder drug formulations and microbeads were very low or negligible, however, at higher concentrations, we discovered equivalent or increasing effects of the drugs loaded in microbeads. CONCLUSIONS: The study provides evidence that microbead formulations of the hydrolytically labile azanucleoside drugs could prevent their chemical decomposition in aqueous solution, and effectively increase plasma circulation time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17012972
003      
CZ-PrNML
005      
20170517081921.0
007      
ta
008      
170413s2016 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2016.013 $2 doi
035    __
$a (PubMed)27003313
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Hrubý, Martin, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1978 prosinec 15.- $7 xx0060770
245    10
$a Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs / $c M. Hruby, K. Agrawal, O. Policianova, J. Brus, J. Skopal, P. Svec, M. Otmar, P. Dzubak, P. Stepanek, M. Hajduch
520    9_
$a BACKGROUND: The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs is confounded by their hydrolytic lability which decreases plasma circulation time. Here, we describe a new biodegradable, polyanhydride formulation for drug delivery that circumvents this drawback. METHODS: Injectable/implantable polymeric microbeads containing dispersed microcrystals of hydrophilic AZA or DAC packed in a dry environment are protected from hydrolysis, until the hydrolytic zone reaches the core. Diclofenac is embedded into the formulation to decrease any local inflammation. The efficacy of the formulations was confirmed by monitoring the induced demethylation, and cytostatic/cytotoxic effects of continuous drug release from the time-course dissolution of the microbeads, using an in vitro developed cell based reporter system. RESULTS: Poly(sebaccic acid-co-1,4-cyclohexanedicarboxylic acid) containing 30 wt. % drug showed zero-order release (R(2) = 0.984 for linear regression), and release rate of 10.0 %/h within the first 5 h, and subsequent slower release of the remaining drug, thus maintaining the level of drugs in the outer environment considerably longer than the typical plasma half-life of free azanucleosides. At lower concentrations, the differences between powder drug formulations and microbeads were very low or negligible, however, at higher concentrations, we discovered equivalent or increasing effects of the drugs loaded in microbeads. CONCLUSIONS: The study provides evidence that microbead formulations of the hydrolytically labile azanucleoside drugs could prevent their chemical decomposition in aqueous solution, and effectively increase plasma circulation time.
650    _2
$a vstřebatelné implantáty $7 D020341
650    _2
$a protinádorové antimetabolity $x aplikace a dávkování $x farmakologie $7 D000964
650    _2
$a azacytidin $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D001374
650    _2
$a kultivované buňky $7 D002478
650    _2
$a lidé $7 D006801
650    _2
$a implantabilní infuzní pumpy $7 D015918
650    _2
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a mikrosféry $7 D008863
650    _2
$a polymery $x chemie $7 D011108
655    _2
$a časopisecké články $7 D016428
700    1_
$a Agrawal, Kushboo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 _AN073524
700    1_
$a Policianova, Olivia $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
700    1_
$a Brus, Jiří, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1970- $7 jo2011640489
700    1_
$a Skopal, Jan $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
700    1_
$a Švec, Pavel $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $7 _AN089436
700    1_
$a Otmar, Miroslav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $7 xx0121125
700    1_
$a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0080445
700    1_
$a Štěpánek, Petr, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1952- $7 xx0027070
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0050218
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 2 (2016), s. 222-230
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170425143042 $b ABA008
999    __
$a ok $b bmc $g 1205368 $s 973745
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 160 $c 2 $d 222-230 $e 20160321 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...